

16 α ,17-Epoxy-4-pregnene-3,20-dione

Shi Wang,* Yongli Wang, Qiang Nie, Lina Zhou and Jiehua Wu

College of Chemical Engineering, Tianjin University, Tianjin 300072, People's Republic of China

Correspondence e-mail:
wangshi04@hotmail.com

Key indicators


Single-crystal X-ray study
 $T = 293$ K
Mean $\sigma(\text{C}-\text{C}) = 0.004$ Å
 R factor = 0.038
 wR factor = 0.092
Data-to-parameter ratio = 10.9For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

The title compound, $\text{C}_{21}\text{H}_{28}\text{O}_3$, is a steroid derivative used as an intermediate in medicine. The molecular structure corresponds to an earlier determination [Goubitz *et al.* (1984). *Steroids*, **44**, 153–158]. However, the orthorhombic unit-cell parameters of the two determinations are significantly different, and these structures are polymorphs.

Received 1 November 2004
Accepted 10 November 2004
Online 20 November 2004

Comment

The title compound, (I), a steroid derivative, was prepared from diosgeum. In the solid state, ring *A* has a 1α -sofa conformation (Fig. 1), rings *B* and *C* have chair conformations and ring *D* has a 14α -envelope conformation. These molecular conformations are similar to those published earlier (Goubitz *et al.*, 1984) for the same compound with the Cambridge Structural Database (Version 5.25; Allen, 2002) refcode DILYEC, (II). However, the orthorhombic unit-cell parameters of (II) [$a = 13.8635$ Å, $b = 17.283$ Å and $c = 7.424$ Å] are markedly different from those for (I), so these are polymorphs. Interestingly, the CSD contains a crystal structure (refcode BUPRGE10; Tseikinskii *et al.*, 1980) with orthorhombic unit-cell parameters [$a = 7.53$ Å, $b = 13.94$ Å and $c = 17.31$ Å] quite close to those for (II). The chemical identity of BUPRGE10, namely $16\alpha,17\alpha$ -cyclopropano-progesterone, is only slightly different from that of (II), with a CH_2 group instead of the epoxide O atom; the two compounds are essentially isostructural.



In the crystal structure, there are short intermolecular C—H...O contacts (Table 1). The molecular structure (Fig. 1) and crystal packing (Fig. 2) of (I) are similar to those in 11-hydroxy-16,17-epoxypregn-4-ene-3,20-dione (Wang *et al.*, 2004), which can be obtained from (I) by fermentation.

Experimental

$16\alpha,17$ -Epoxy-4-pregnene-3,20-dione was prepared from diosgeum by hydrolyzation and oxidation, and is a product of the Tianjin Tianyao Pharmaceutical Co. Ltd. The product was characterized by NMR, IR and elemental analyses, and its purity was 99%. The




Figure 1
ORTEP (Johnson, 1976) view of the title compound, showing 30% probability displacement ellipsoids.

melting point of the compound was 482.8 K, measured by differential scanning calorimetry, and its solubility is 0.123 g/g (293 K) in toluene. Colorless single crystals suitable for X-ray diffraction were obtained by slow evaporation in air of a toluene solution with a concentration of 0.1 g/g (293 K).

Crystal data

$C_{21}H_{28}O_3$	Mo $K\alpha$ radiation
$M_r = 328.43$	Cell parameters from 16882 reflections
Orthorhombic, $P2_12_12_1$	$\theta = 2.0\text{--}27.5^\circ$
$a = 7.3357$ (1) Å	$\mu = 0.08$ mm $^{-1}$
$b = 12.1537$ (2) Å	$T = 293$ (2) K
$c = 20.3204$ (1) Å	Block, colorless
$V = 1811.68$ (4) Å 3	$0.73 \times 0.40 \times 0.31$ mm
$Z = 4$	
$D_x = 1.204$ Mg m $^{-3}$	

Data collection

Rigaku R-AXIS RAPID IP diffractometer	2380 independent reflections
ω and φ scans	1311 reflections with $I > 2\sigma(I)$
Absorption correction: multi-scan (ABSCOR; Higashi, 1995)	$R_{int} = 0.070$
$T_{min} = 0.945, T_{max} = 0.976$	$\theta_{max} = 27.5^\circ$
16882 measured reflections	$h = -8 \rightarrow 9$
	$k = -14 \rightarrow 15$
	$l = -25 \rightarrow 26$

Refinement

Refinement on F^2	$w = 1/[\sigma^2(F_o^2) + (0.0442P)^2]$
$R[F^2 > 2\sigma(F^2)] = 0.038$	where $P = (F_o^2 + 2F_c^2)/3$
$wR(F^2) = 0.092$	$(\Delta/\sigma)_{max} = 0.001$
$S = 0.83$	$\Delta\rho_{max} = 0.14$ e Å $^{-3}$
2380 reflections	$\Delta\rho_{min} = -0.19$ e Å $^{-3}$
218 parameters	Extinction correction: SHELXL97
H-atom parameters constrained	Extinction coefficient: 0.028 (2)

Table 1
Hydrogen-bonding geometry (Å, °).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
C11—H11A \cdots O2 ⁱ	0.97	2.52	3.433 (3)	158
C6—H6B \cdots O1 ⁱⁱ	0.97	2.43	3.371 (3)	164

Symmetry codes: (i) $x - \frac{1}{2}, \frac{1}{2} - y, 1 - z$; (ii) $1 - x, y - \frac{1}{2}, \frac{1}{2} - z$.




Figure 2
The molecular packing of the title compound, viewed along the a axis. Dashed lines indicate the intermolecular short contacts.

All H atoms were placed in geometrically idealized positions ($C-H = 0.93\text{--}0.98$ Å) and constrained to ride on their parent atoms, with $U_{iso}(H) = 1.2U_{eq}(C)$. In the absence of significant anomalous dispersion effects, Friedel pairs were merged before the final refinement and the absolute configuration was assigned to correspond with that of the known chiral centres in a precursor molecule, which remained unchanged during the synthesis of the title compound.

Data collection: RAPID-AUTO (Rigaku, 2001); cell refinement: RAPID-AUTO; data reduction: RAPID-AUTO; program(s) used to solve structure: SHELXS97 (Sheldrick, 1997); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997); molecular graphics: ORTEP (Johnson, 1976); software used to prepare material for publication: SHELXL97.

We gratefully acknowledge support from the SRCICT of Tianjin University and the provision of the product by the Tianjin Tianyao Pharmaceutical Co. Ltd.

References

Allen, F. H. (2002). *Acta Cryst.* **B58**, 380–388.
 Goubitz, K., Schenk, H. & Zeelen, F. J. (1984). *Steroids*, **44**, 153–158.
 Higashi, T. (1995). *ABSCOR*. Rigaku Corporation, Tokyo, Japan.
 Johnson, C. K. (1976). *ORTEP*. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.
 Rigaku (2001). *RAPID-AUTO*. Rigaku Corporation, 3-9-12 Akishima, Tokyo, Japan.
 Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
 Tseikinskii, V. M., Rybakov, V. B., Simonov, V. I., Kamenitskii, A. V., Ignatov, V. N. & Levina, I. S. (1980). *Bioorg. Khim.* **6**, 752–759.
 Wang, Y., Wang, S., Hao, H., Chen, W. & Nie, Q. (2004). *Acta Cryst.* **E60**, o1338–o1339.